Rezdiffra (Resmetirom) in Hispanic and Latino Patients: Documented Efficacy Gaps and Pharmacogenomic Considerations
Evidence-based review of resmetirom (Rezdiffra) efficacy in Hispanic and Latino populations, including MAESTRO-NASH subgroup data, CYP enzyme variants, and clinical dosing considerations for MASH treatment.
Read clinical review